| LA-ESCC | Locally advanced esophageal squamous cell carcinoma |
| ESCC | Esophageal squamous cell carcinoma |
| nCRT | Neoadjuvant chemoradiotherapy |
| nCIT | Neoadjuvant chemotherapy plus immunotherapy |
| OS | Overall survival |
| PFS | Progression-free survival |
| DFS | Disease-free survival |
| pCR | Pathologic complete response |
| ORR | Objective response rate |
| MPR | Major pathological response |
| PSM | Propensity score matching |
| TP | Taxane plus platinum |
| TRAEs | Treatment-related adverse events |
| AEs | Adverse events |
| PD-L1 | Programmed death-ligand 1 |
| TMB | Tumor mutational burden |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.